Late coronary stent thrombosis and clopidogrel

Česká verzia

Authors: I. Varvařovský; J. Matějka; A. Herman
Authors place of work: Pracoviště invazivní kardiologie Kardio-Troll, Krajská nemocnice Pardubice, přednosta prim. MUDr. Aleš Herman, Ph. D.
Published in the journal: Vnitř Lék 2007; 53(10): 1085-1091
Category: Reviews

Summary

The existence of late coronary stent thrombosis is a topical issue in cardiology today. The synoptic article discusses current definition of the above phenomenon, its delimitation in time and actual incidence. Based on data from available observation and randomised studies, long-term safety of conventional bare metal and drug-eluting stents is evaluated, as well as the safety profile following implantation. The length of thienopyridin treatment after percutaneous coronary intervention (PCI) varies according to the type of stent used. While a conventional bare metal stent (BMS) implant provides long-term safety with one month treatment, the implantation of a drug-eluting stent (DES) should be complemented with a 12-month period of clopidogrel administration. This approach may be in the future influenced by further progress in drug-eluting stents development and by prospectively acquired information on long-term administration of clopidogrel to such patients.

Keywords:
late coronary stent thrombosis – drug-eluting stents – clopidogrel

Zdroje

1. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-1720.

2. Sigwart U. Endoluminal stenting. 1st ed. London: WB Saunders 1996: 601.

3. Mak KH, Belli G, Ellis SG Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996; 27: 494-503.

4. Orford JL, Lennon R, Melby S. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 2002; 40: 1567-1572.

5. Ong AT, Hoye A, Aoki J. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947-953.

6. Krotz F, Sohn HY, Klauss V. Intracoronary brachytherapy-clinical state and pathophysiological considerations. Curr Pharm Des 2005; 11: 421-433.

7. Joner M, Finn AV, Farb A. Pathology of drug-eluting stents i humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 203-205.

8. Farb A, Burke AP, Kolodgie FD. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003; 108:1701-1706.

9. Hong MK, Mintz GS, Lee CW. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 2004; 109: 881-886.

10. Virmani R, Guagliumi G, Farb A. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.

11. Feres F, Costa JR, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 2006; 68: 83-88.

12. Lev EI, Alviar CL, Arikan ME. Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. Am Heart J 2007; 153: e1-e6.

13. Bavry AA, Chiu JH, Jefferson BK. Development of coronary aneurysma after drug-eluting stent implantation. Ann Intern Med 2007; 144: e-publikace 4.12.2006.

14. Serruys PW, Strauss BH, Beatt KJ. Angiographic follow-up after placement of a self-expanding coronary artery stent. N Engl J Med 1991; 324: 13-17.

15. Colombo A, Hall P, Nakamura S. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-1688.

16. Leon MB, Baim DS, Popma JJ. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. N Engl J Med 1998; 339: 1665-1671.

17. Berger PB, Mahaffey KW, Meier SJ. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J 2002; 143: 841-846.

18. Bertrand ME, Rupprecht HJ, Urban P. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.

19. Bhatt DL, Bertrand ME, Berger PB. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14.

20. Costa MA, Sabate M, van der Giessen WJ. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999; 100: 789-792.

21. Weisz G, Moses JW, Schofer J. Late stent thrombosis in sirolimus-eluting versus bare-metal stents in 4 randomized clinical trials with 3-year follow-up. J Am Coll Cardiol 2006; 47 Suppl B: 8B.

22. Wang F, Stouffer GA, Waxman S. Late coronary stent thrombosis: early vs late stent thrombosis in the stent era. Catheter Cardiovasc Interv 2002; 55: 142-147.

23. Bhatt DL, Fox KAA, Hacke W Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.

24. Connolly SJ. The Atrial Fibrilation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Late Breaking Clinical Trials III, AHA Scientific Session 2005, Dallas, November 13-16, 2005.

25. Eisenstein EL, Anstrom KJ, Kong DF. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-168.

26. Steinhubl SR, Berger PB, Tift Mann J 3rd. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.

27. Mehta S, Yusuf S, Peters RJG. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.

28. Smith SC, Feldman TE, Hirshfeld JW. ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention - Summary Article. J Am Coll Cardiol 2006; 47: 216-235.

29. Silber S, Albertsson P, Aviles FF. Guidelines for percutaneous coronary intervention. Eur Heart J 2005; 26: 804-847.

30. Morice MC, Serruys PW, Sousa JE. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.

31. Grube E, Silber S, Hauptman KE. TAXUS-I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo lesion. Circulation 2003; 107: 38-42.

32. Stone GW, Ellis SG, Cox DA. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-197.

33. Morice MC, Colombo A, Meier B. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions. The REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904.

34. Fajadet J, Wijns W, Laarman GJ. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesion: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.

35. Kerner A, Gruberg L, Kapeliovich M. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv 2003; 60: 505-508.

36. Babapulle MN, Joseph L, Belisle P. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.

37. McFadden EP, Stabile E, Regar E. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.

38. Ong AT, McFadden EP, Regar E. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-2092.

39. Iakovou I, Schmidt T, Bonizzoni E Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 30.

40. Kuchulakanti PK, Chu WW, Torguson R Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113: 1108-1113.

41. Moreno R, Fernandez C, Hernandez R. Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45: 954-959.

42. Rao SV, Shaw RE, Brindis RG. On- versus off-label use of drug-eluting coronary stents in clinical practice. Report from the American College of Cardiology National Cardiovascular Data Registry. Am J Cardiol 2006; 97: 1478-1481.

43. Carlsson J, von Wagenheim B, Linder R Is late stent thrombosis in drug-eluting stents a real clinical issue? A single center experience and review of the literature. Clin Res Cardiol 2006; 95: e-publikace 22.12.2006.

44. Lagerqvist B, James SK, Stenestrand U. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.

45. Kaiser C, Brunner-La Rocca HP, Buser PT. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921-929.

46. Pfisterer M, Brunner-La Rocca HP, Buser PT. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.

47. Spertus JA, Kettelkamp R, Vance C. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Results from the PREMIER registry. Circulation 2006; 113: 2803-2809.